Jefferies analyst Hisae Kawamoto upgraded Kobayashi Pharmaceutical (KBYPF) to Hold from Underperform with an unchanged price target of 4,900 yen. The pace of increase in the number of people affected by the red yeast rice issue has been stable for the past four months and with the presentation of measures to prevent recurrence and the revision of the mid-term plan next year, the firm believes that “excessive concerns have been allayed and that new events are more likely to be to the upside,” the analyst tells investors.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KBYPF:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
